The San Francisco, CA-based biopharmaceutical firm
develops therapies for liver and cardio-metabolic diseases. Lead
candidate is BIO89-100,
an engineered gycoPEGylated (drug works in the body longer) analog of
fibroblast growth factor 21 (FGF21), for the potential treatment of
nonalcoholic steatohepatitis (NASH). A Phase 1b/2 clinical trial
launched in July with topline data expected in H2 2020.
2019 Financials (6
mo.)(comparison period is not exact since inception was 1/18/18):
Operating Expenses: $8.8M (+27%); Net Loss: ($19.4M) (-162%); Cash Burn:
($8.1M) (-22%).
https://seekingalpha.com/news/3505364-89bio-deck-ipo
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.